Randomized Double Blind (Sponsor Unblind) Study Evaluating the Effect of 14 Days of Treatment With Danirixin (GSK1325756) on Neutrophil Extracellular Traps (NETs) Formation in Participants With Stable Chronic Obstructive Pulmonary Disease (COPD)
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 20 Nov 2017 Status changed from not yet recruiting to recruiting.
- 03 Oct 2017 Planned End Date changed from 7 Jun 2018 to 10 Jul 2018.
- 03 Oct 2017 Planned primary completion date changed from 7 Jun 2018 to 10 Jul 2018.